[go: up one dir, main page]

US2783241A - S-acylimino-x-substituted-az-i - Google Patents

S-acylimino-x-substituted-az-i Download PDF

Info

Publication number
US2783241A
US2783241A US2783241DA US2783241A US 2783241 A US2783241 A US 2783241A US 2783241D A US2783241D A US 2783241DA US 2783241 A US2783241 A US 2783241A
Authority
US
United States
Prior art keywords
thiadiazoline
parts
sulfonamide
volume
acetylimino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Publication date
Application granted granted Critical
Publication of US2783241A publication Critical patent/US2783241A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • This invention relates to a new series of organic compounds. More particularly, this invention is concerned with certain 5 acylimino 4 substituted-A l,3,4-thiadizoline-Z-sulfonamides and methods for their preparation.
  • sulfanarnide drugs have come into prominence in recent years with the discovery by Clapp and Roblin (U. S. Patent No. 2,554,816) that certain heterocyclic sulfonamides are desirable diuretic agents because of their ability to inhibit the enzyme carbonic anhydrase. Because of this property, these agents have found utility in the treatment of certain diseases associated with fluid retention in the body such as congestive heart failure.
  • the compounds of the present invention may be represented by the following general formula:
  • R1 is a hydrogen atom, a lower alkyl or a monocyclic aralkyl substituent and R2 is a lower alkyl or a monocyclic aralkyl substituent.
  • lower alkyl radicals may be given methyl, ethyl, propyl, isopropyl, butyl and isobutyl.
  • Suitable aralkyl substituents are benzyl, a-phenethyl, phenylpropyl and phenylbutyl.
  • Compounds of the present invention can be prepared by chlorinating the 5-acylimino-4-substituted-2-benzylmercapto-A -1,3,4-thiadiazoline starting material to the
  • the chlolination may be accomplished by passing chlorine gas through either a suspension or a solution of the starting material in an aqueous acid.
  • the latter is preferred since it enables the operator to determine quickly the point at which the reaction is complete by a color change from colorless to yellow whereas this point is difficult to determine when a suspension is employed. It is to be noted, however, that either form is suitable and may be em ployed with equal advantage.
  • the resulting sulfonyl chloride is then converted to the corresponding sulfonamide upon treatment with ammonia in the form of liquid ammonia or ammonium hydroxide, diluted with water, filtered and the solution acidified with a mineral acid such as hydrochloric acid or sulfuric acid.
  • the preferred medium forchlorinating the starting material is a aqueous solution of acetic acid in which the starting materials are completely soluble. If a higher concentration is used, as for example a33% solution, the starting materials will not dissolve and a suspension results. As mentioned above, because of the ease of manipulation it is preferred to employ solutions of the starting material.
  • Other, and equally useful, carriers are hydrobromic acid and hydrochloric acid as well as the lower fatty acids such as formic, propionic or butyric.
  • the mineral acids such as sulfuric acid, hydrochloric acid and phosphoric acid are also useful for this purpose.
  • the starting materials employed in this invention-- namely theS acylimino-4-substituted-Z-benzylmercapto- A -1,3,4-thiadiazolines, may be prepared by alkylating the corresponding 2 acylamino-S-benzylmercapto-1,3,4- thiadiazole with an alkyl halide under suitable reaction conditions.
  • Methyl iodide and benzyl bromide are examples of alkylating agents which may be used.
  • the reaction is preferably conducted in the presence of a sodium alkoxide such as sodium methoxide.
  • the details relating to the preparation of the starting material are completely set forth in the copending U. S. application S. N. 492,298 of Richard W. Young and Kathryn H. Wood, filed concurrently herewith.
  • Example 1 A suspension of 6 parts by weight of 5-acetylimino-4- methyl-Z-beuzylmercapto-A 1,3,4 thiadiazoline in 180 parts by volume of 33% aqueous acetic acid was chlorinated at 5 C. for 30 minutes. The solid was filtered off, dried, and added portion-wise to parts by volume of liquid ammonia. The ammonia was removed under a stream of dry nitrogen. The residual solid was partially dissolved in 10 parts by volume of water, filtered, and acidified to give 5-acetylirniuo-4-methyl A l,3,4- thiadiazoline-Z-sulfonamide. The product was purified by two recrystallizations from, hot water.
  • Example 111 A suspension of 6 parts by weight of 5-acetylimino-4- ethyl-Z-benzylmercapto-A -1,3,4-thiadiazoline in parts by volume of 33% aqueous acetic acid was chlorinated at 5 C. for 30 minutes. The solid was filtered off, dried, and added portion-wise to 100 parts by volume of liquid ammonia. The ammonia was removed under a stream of dry nitrogen. The residual solid was partially dissolved in 10 parts by volume of water, filtered, and acidified to give 5-acetylimino-4-ethyl-A -l,3,4-hiadiazoline-2-sulfonamide. The product was purified by two recrystallizations from hot water.
  • Example IV A 1.18 parts by weight sample of 5-propionylimino-4- methyl-Z-benzylmercapto-A -1,3,4-thiadiazolinc was sus- Platented Feb. 26,
  • Example V A suspension of 6 parts by weight of S-propionylimino- 4-ethyl-2-benzylmercapto-A -1,3,4-thiadiazoline in 180 parts by volume of 33% aqueous acetic acid was chlorinated at 5 C. for 30 minutes. The solid was filtered off, dried, and added portion-wise to 100 parts by volume of liquid ammonia. The ammonia was removed under a stream of dry nitrogen. The residual solid was partially dissolved in 10 parts by volume of water, filtered, and acidified to give 5-p1'opionylimino-4-ethyl-A -1,3,4- thiadiazoline-Z-sulfonamide. The product was purified by two recrystallizations from hot water.
  • Example VI 14 parts by weight of 5-acetylimino-4-methyl-2-benzylmercapto-n -l,3,4-thiadiazoline was dissolved in a solution containing 150 parts by volume of glacial acetic acid and 50 parts by volume of water. The mixture was chlorinated for 10 minutes at 10 C. to 15 C. with chlorine gas until the colorless solution turned a permanent yellow color. The reaction mixture was poured into a mixture of 100 parts by volume of water and 100 parts by weight of ice. A white solid was immediately deposited and was filtered ofi. The dry solid was added to 75 parts by volume of liquid ammonia and the excess evaporated under nitrogen. The reaction mixture was diluted with 100 parts by volume of water, leaving a cloudy solution. Upon acidification with hydrochloric acid, a solid of 5-acetylimino-4-methyl-A -l,3,4-thiadiazoline 2 sulfonamide was deposited, which was filtered off and dried.
  • Example VII Following the procedure set forth in Example VI, 5 acetylirnino-4-benzyl-2-benzylmercapto-A -l,3,4-thiadiazoline may be dissolved in a 10% solution of acetic acid and the mixture chlorinated for 10 minutes at 5 C., with chlorine gas until the solution turns a permanent yellow color.
  • the sulfonyl chloride derivative is obtained by pouring the reaction mixture into a mixture of 100 parts by volume of water and 100 parts by weight of ice. The white solid which deposits, is filtered off. The dry solid is added to 75 parts by volume ofliquid ammonia and the excess is evaporated under nitrogen.
  • R1 is a member selected from the group consisting of hydrogen atoms, lower 'alkyl and lower-alkyl and phenyl-lower-alkyl radicals and R2 is a member selected from the group consisting of lower alkyl andphenyl-loweralkyl radicals.
  • R1 is a member selected from the group consisting of hydrogen, lower alkyl and phenyl-lower-alkyl radicals and R2 is a member selected from the group consisting of the lower alkyl and phenyl-lower-alkyl radicals which comprises chlorinating a member selected from the group consisting of 5-acylimino-4-lower alkyl-Z-benzylrnercapto-A -1,3,4-thiadiazolines and 5 -acylimino-4- phenyl-loweralkyl- 2 -benzylmercapto-A -1,3,4'thiadiazolines in aqueous acid to, obtain the corresponding sulfonyl chloride derivative, and then reacting said derivative with ammonia.
  • a method for preparing 5-acetylimino-4-methyl-A l,3,4-thiadiazoline-Z-sulfonamide which comprises chlorinating 5-acetylimino-4-methyl-2-benzylmercapto-A -1,3,- 4thiadiazoline in aqueous acid, and then reacting the resulting sulfonyl chloride derivative with ammonia.
  • a method 'for preparing 5-acetylimino-4-benzyl-A 1,3,4-thiadiazoline-Z-sulfonamide which comprises chlorinating 5-acetylimino-4-benzyl-2-benzylmercapto-A -1,3,- 4-thiadiazoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia.
  • a method for preparing 5-acetylimino-4-ethylA l,3,4-thiadiazoline-2-sulfonamide which comprises chlo rinating 5 aceylimino-4-ethyl-2-benzylmercapto-n -1,3,4- thiadiazoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia.
  • a method for preparing 5-propionyl-4methyl-A 1,3,4-thiadiazoline-2-sulfonamide which comprises chlorinating S-propionylimino-4-methyl-2-benzylmercapto-A 1,3,4-thiadiazoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia.
  • a method for preparing 5-propionyl-4-etl1yl-A 1,3,4-thiadiazoline-Z-sulfonamide which comprises chlorinating 5-propionylimino-4-ethyl-2-benzylrnercapto-A -1,- 3,4-thiadi-azoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Description

; corresponding 2-sulfonyl chloride derivative.
2,783,241 S-ACYLIMINO -4- SUBSTITUTED-A -1,3,4-THIADI- AZOLINE-Z-SULFONAMIDES AND METHODS FOR THEIR PREPARATION Richard William Young, Riverside, Kathryn Helen Wood, Old Greenwich, and James Robert Vaughan, Jr., Darien, Conn., assignors to American Cyanamid Company, New York, N. Y., a corporation of Maine No Drawing. Application March 4, 1955, Serial No. 492,297 12 Claims. (Cl. 260306.8)
This invention relates to a new series of organic compounds. More particularly, this invention is concerned with certain 5 acylimino 4 substituted-A l,3,4-thiadizoline-Z-sulfonamides and methods for their preparation.
The sulfanarnide drugs have come into prominence in recent years with the discovery by Clapp and Roblin (U. S. Patent No. 2,554,816) that certain heterocyclic sulfonamides are desirable diuretic agents because of their ability to inhibit the enzyme carbonic anhydrase. Because of this property, these agents have found utility in the treatment of certain diseases associated with fluid retention in the body such as congestive heart failure.
We have now discovered a new series of compounds which are also capable of inhibiting carbonic anhydrase. in vivo tests of these compounds indicate that they are longer-acting inhibitors and that therapeutic levels of these drugs may be maintained over a longer period of time resulting in greater diuresis. The tests also show that our compounds are able to penetrate into the cerebro spinal fluid through the bloodzbrain barrier and into the ocular fluid through the bloodzocular fluid barrier. For this reason they are superior to other known compounds of this class in the treatment of glaucoma and epilepsy.
The compounds of the present invention may be represented by the following general formula:
wherein R1 is a hydrogen atom, a lower alkyl or a monocyclic aralkyl substituent and R2 is a lower alkyl or a monocyclic aralkyl substituent. As examples of lower alkyl radicals may be given methyl, ethyl, propyl, isopropyl, butyl and isobutyl. Suitable aralkyl substituents are benzyl, a-phenethyl, phenylpropyl and phenylbutyl.
Compounds of the present invention can be prepared by chlorinating the 5-acylimino-4-substituted-2-benzylmercapto-A -1,3,4-thiadiazoline starting material to the The chlolination may be accomplished by passing chlorine gas through either a suspension or a solution of the starting material in an aqueous acid. The latter is preferred since it enables the operator to determine quickly the point at which the reaction is complete by a color change from colorless to yellow whereas this point is difficult to determine when a suspension is employed. It is to be noted, however, that either form is suitable and may be em ployed with equal advantage. The resulting sulfonyl chloride is then converted to the corresponding sulfonamide upon treatment with ammonia in the form of liquid ammonia or ammonium hydroxide, diluted with water, filtered and the solution acidified with a mineral acid such as hydrochloric acid or sulfuric acid.
The preferred medium forchlorinating the starting material is a aqueous solution of acetic acid in which the starting materials are completely soluble. If a higher concentration is used, as for example a33% solution, the starting materials will not dissolve and a suspension results. As mentioned above, because of the ease of manipulation it is preferred to employ solutions of the starting material. Other, and equally useful, carriers are hydrobromic acid and hydrochloric acid as well as the lower fatty acids such as formic, propionic or butyric. The mineral acids such as sulfuric acid, hydrochloric acid and phosphoric acid are also useful for this purpose.
The starting materials employed in this invention-- namely theS acylimino-4-substituted-Z-benzylmercapto- A -1,3,4-thiadiazolines, may be prepared by alkylating the corresponding 2 acylamino-S-benzylmercapto-1,3,4- thiadiazole with an alkyl halide under suitable reaction conditions. Methyl iodide and benzyl bromide are examples of alkylating agents which may be used. The reaction is preferably conducted in the presence of a sodium alkoxide such as sodium methoxide. The details relating to the preparation of the starting material are completely set forth in the copending U. S. application S. N. 492,298 of Richard W. Young and Kathryn H. Wood, filed concurrently herewith.
The utility of the present invention is illustrated by the following examples, which are intended to be merely illustrative and not limitative upon the scope thereof.
. All parts are by weight unless otherwise specified.
Example 1 A suspension of 6 parts by weight of 5-acetylimino-4- methyl-Z-beuzylmercapto-A 1,3,4 thiadiazoline in 180 parts by volume of 33% aqueous acetic acid was chlorinated at 5 C. for 30 minutes. The solid was filtered off, dried, and added portion-wise to parts by volume of liquid ammonia. The ammonia was removed under a stream of dry nitrogen. The residual solid was partially dissolved in 10 parts by volume of water, filtered, and acidified to give 5-acetylirniuo-4-methyl A l,3,4- thiadiazoline-Z-sulfonamide. The product was purified by two recrystallizations from, hot water.
Exampie II A 1.18 parts by Weight sample of S-acetyliminolbenzyl-2-benzylmercapto-A l,3,4-thiadiazoline was sus pended in 30 parts by volume of 33% acetic acid and the mixture chlorinated at 5 C. for 30 minutes. The solid sulfonyl chloride derivative was filtered off, washed with Water and dissolved in 50 parts by volume of ether. This solution was dried and added to about 10 parts by volume of liquid ammonia. The excess ammonia and solvent were removed by distillation and the residue was redissolved in cold water. On acidifying this solution, the crude 5-acetylimino-4-benZyl-A -1,3,4-thiadiazoline- 2-sulfonamide was precipitated as a colorless solid. The product was purified by crystallization twice from 50% ethanol and then from a mixture of ethyl acetate and petroleum ether.
Example 111 A suspension of 6 parts by weight of 5-acetylimino-4- ethyl-Z-benzylmercapto-A -1,3,4-thiadiazoline in parts by volume of 33% aqueous acetic acid was chlorinated at 5 C. for 30 minutes. The solid was filtered off, dried, and added portion-wise to 100 parts by volume of liquid ammonia. The ammonia was removed under a stream of dry nitrogen. The residual solid was partially dissolved in 10 parts by volume of water, filtered, and acidified to give 5-acetylimino-4-ethyl-A -l,3,4-hiadiazoline-2-sulfonamide. The product was purified by two recrystallizations from hot water.
Example IV A 1.18 parts by weight sample of 5-propionylimino-4- methyl-Z-benzylmercapto-A -1,3,4-thiadiazolinc was sus- Platented Feb. 26,
pended in 30 parts by volume of 33% acetic acid and the mixture chlorinated at C. for 30 minutes. The solid sulfonyl chloride derivative was filtered off, washed with water and dissolvedin 50 parts by volume of ether. This solution was dried and added to about parts by volume of liquid ammonia. The excess ammonia and solvent were removed by distillation and the residue was redissolved in cold water. On acidifying this solution, the crude 5-propionyliinino-4-methyl-A -1,3,4-thiadiazoline- 2-sulf0namide was precipitated as a colorless solid. The product was purified by crystallization twice from 50% ethanol and then from a mixture of ethyl acetate and petroleum ether. Example V A suspension of 6 parts by weight of S-propionylimino- 4-ethyl-2-benzylmercapto-A -1,3,4-thiadiazoline in 180 parts by volume of 33% aqueous acetic acid was chlorinated at 5 C. for 30 minutes. The solid was filtered off, dried, and added portion-wise to 100 parts by volume of liquid ammonia. The ammonia was removed under a stream of dry nitrogen. The residual solid was partially dissolved in 10 parts by volume of water, filtered, and acidified to give 5-p1'opionylimino-4-ethyl-A -1,3,4- thiadiazoline-Z-sulfonamide. The product was purified by two recrystallizations from hot water.
Example VI 14 parts by weight of 5-acetylimino-4-methyl-2-benzylmercapto-n -l,3,4-thiadiazoline was dissolved in a solution containing 150 parts by volume of glacial acetic acid and 50 parts by volume of water. The mixture was chlorinated for 10 minutes at 10 C. to 15 C. with chlorine gas until the colorless solution turned a permanent yellow color. The reaction mixture was poured into a mixture of 100 parts by volume of water and 100 parts by weight of ice. A white solid was immediately deposited and was filtered ofi. The dry solid was added to 75 parts by volume of liquid ammonia and the excess evaporated under nitrogen. The reaction mixture was diluted with 100 parts by volume of water, leaving a cloudy solution. Upon acidification with hydrochloric acid, a solid of 5-acetylimino-4-methyl-A -l,3,4-thiadiazoline 2 sulfonamide was deposited, which was filtered off and dried.
Example VII Following the procedure set forth in Example VI, 5 acetylirnino-4-benzyl-2-benzylmercapto-A -l,3,4-thiadiazoline may be dissolved in a 10% solution of acetic acid and the mixture chlorinated for 10 minutes at 5 C., with chlorine gas until the solution turns a permanent yellow color. The sulfonyl chloride derivative is obtained by pouring the reaction mixture into a mixture of 100 parts by volume of water and 100 parts by weight of ice. The white solid which deposits, is filtered off. The dry solid is added to 75 parts by volume ofliquid ammonia and the excess is evaporated under nitrogen. Dilution with 100 parts by volume of water leaves a cloudy solution which, upon acidification with hydrochloric acid, yields 5-acetylimino-4-benzyl-A -l,3,4-thiadiazoline-Z-sulfonamide, which is filtered 06 and dried.
The following listed compounds may be prepared by following the procedure described in Example I, employing as a starting material the appropriate 5-acylimino-4- substituted-Z-benzylmercapto-M-1,3,4-thiadiazoline:
5-formylimino-4methyl-A -1,3,4-thiadiazoline 2 sulfonamide 5 butyrylimino 4 methyl A 1,3,4 thiadiazoline- 2-su1fonamide 5 butyrylimino 4 benzyl A 1,3,4 thiadiazoline- 2-sulfonamide 5 acetylimino 4 p nitrobenzyl A 1,3,4 thiadiazoline-Z-sulfonamide 5 acetylimino 4 butyl A 1,3,4 thiadiazoline 2 sulfonamide 4 5 propionylimino 4 butyl A 1,3,4 thiadiazoline- 2-sulfonamide We claim: 1. A compound selected from the group consisting of those having the general formula:
wherein R1 is a member selected from the group consisting of hydrogen atoms, lower 'alkyl and lower-alkyl and phenyl-lower-alkyl radicals and R2 is a member selected from the group consisting of lower alkyl andphenyl-loweralkyl radicals.
2. The compound 5-acetylimino-4-methyl-A -l,3,4-thiadiazoline-Z-sulfonamide.
3. The compound 5-acetylimino-4-benzyl-A -l,3,4-thiadiazoline-Z-sulfonamide.
4. The compound 5 -acetylimino-4-cthyl-M-l,3,4-thiadiazoline-Z-sulfonamide.
5. The compound 5-propionylimino-4-methyl-A 1,3,4- thiadiazoline-Z-sulfonamide.
6. The compound 5 propionylimino-4-ethyl-A -l,3,4- thiadiazoline-Z-sulfonamide.
7. A method for preparing compounds selected from the group consisting of those having the general formula:
Ric-Ni J8 OINHI wherein R1 is a member selected from the group consisting of hydrogen, lower alkyl and phenyl-lower-alkyl radicals and R2 is a member selected from the group consisting of the lower alkyl and phenyl-lower-alkyl radicals which comprises chlorinating a member selected from the group consisting of 5-acylimino-4-lower alkyl-Z-benzylrnercapto-A -1,3,4-thiadiazolines and 5 -acylimino-4- phenyl-loweralkyl- 2 -benzylmercapto-A -1,3,4'thiadiazolines in aqueous acid to, obtain the corresponding sulfonyl chloride derivative, and then reacting said derivative with ammonia.
8. A method for preparing 5-acetylimino-4-methyl-A l,3,4-thiadiazoline-Z-sulfonamide which comprises chlorinating 5-acetylimino-4-methyl-2-benzylmercapto-A -1,3,- 4thiadiazoline in aqueous acid, and then reacting the resulting sulfonyl chloride derivative with ammonia.
9. A method 'for preparing 5-acetylimino-4-benzyl-A 1,3,4-thiadiazoline-Z-sulfonamide which comprises chlorinating 5-acetylimino-4-benzyl-2-benzylmercapto-A -1,3,- 4-thiadiazoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia.
10. A method for preparing 5-acetylimino-4-ethylA l,3,4-thiadiazoline-2-sulfonamide which comprises chlo rinating 5 aceylimino-4-ethyl-2-benzylmercapto-n -1,3,4- thiadiazoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia.
11. A method for preparing 5-propionyl-4methyl-A 1,3,4-thiadiazoline-2-sulfonamide which comprises chlorinating S-propionylimino-4-methyl-2-benzylmercapto-A 1,3,4-thiadiazoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia.
12. A method for preparing 5-propionyl-4-etl1yl-A 1,3,4-thiadiazoline-Z-sulfonamide which comprises chlorinating 5-propionylimino-4-ethyl-2-benzylrnercapto-A -1,- 3,4-thiadi-azoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia.
References Cited in the file of this patent UNITED STATES PATENTS 2,554,816 H ..Clapp et al.;. May 29, 1951

Claims (1)

1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF THOSE HAVING THE GENERAL FORMULA:
US2783241D S-acylimino-x-substituted-az-i Expired - Lifetime US2783241A (en)

Publications (1)

Publication Number Publication Date
US2783241A true US2783241A (en) 1957-02-26

Family

ID=3446358

Family Applications (1)

Application Number Title Priority Date Filing Date
US2783241D Expired - Lifetime US2783241A (en) S-acylimino-x-substituted-az-i

Country Status (1)

Country Link
US (1) US2783241A (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2971909A (en) * 1957-12-06 1961-02-14 Standard Oil Co Non-corrosive lubricant compositions
US2978457A (en) * 1959-04-06 1961-04-04 Merck & Co Inc 5-acylamido-4-substituted-thiazole-2-sulfonamides having diuretic properties
US3157572A (en) * 1961-01-06 1964-11-17 American Cyanamid Co Parenteral diuretic compositions of 5-acylimino-4-substituted-delta2-1, 3, 4-thiadiazolidine-2-sulfonamides
US4264616A (en) * 1980-08-29 1981-04-28 Gulf Oil Corporation 2-Iodoacetylimino-3-methyl-5-trifluoromethyl-1,3,4-thiadiazol-4-ine and use as a fungicide
US5776489A (en) * 1989-09-21 1998-07-07 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US6878703B2 (en) 2000-11-21 2005-04-12 Sankyo Company, Limited Pharmaceutical composition
US20060247272A1 (en) * 2004-09-23 2006-11-02 Pfizer Inc 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008089521A1 (en) 2007-01-25 2008-07-31 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2015012205A1 (en) 2013-07-23 2015-01-29 第一三共株式会社 Medicine for preventing or treating hypertension
US20150150855A1 (en) * 2012-05-24 2015-06-04 Verva Pharmaceuticals Ltd Method of improving liver function
US20150174108A1 (en) * 2012-05-24 2015-06-25 Vera Pharmaceuticals Ltd Method of weight reduction
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554816A (en) * 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554816A (en) * 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2971909A (en) * 1957-12-06 1961-02-14 Standard Oil Co Non-corrosive lubricant compositions
US2978457A (en) * 1959-04-06 1961-04-04 Merck & Co Inc 5-acylamido-4-substituted-thiazole-2-sulfonamides having diuretic properties
US3157572A (en) * 1961-01-06 1964-11-17 American Cyanamid Co Parenteral diuretic compositions of 5-acylimino-4-substituted-delta2-1, 3, 4-thiadiazolidine-2-sulfonamides
US4264616A (en) * 1980-08-29 1981-04-28 Gulf Oil Corporation 2-Iodoacetylimino-3-methyl-5-trifluoromethyl-1,3,4-thiadiazol-4-ine and use as a fungicide
US5776489A (en) * 1989-09-21 1998-07-07 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
US6878703B2 (en) 2000-11-21 2005-04-12 Sankyo Company, Limited Pharmaceutical composition
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US20060247272A1 (en) * 2004-09-23 2006-11-02 Pfizer Inc 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008089521A1 (en) 2007-01-25 2008-07-31 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment
US20110003740A1 (en) * 2007-01-25 2011-01-06 Verva Pharmaceuticals Ltd. Insulin sensitisers and methods of treatment
US8455432B2 (en) 2007-01-25 2013-06-04 Verva Pharmaceuticals Ltd. Insulin sensitisers and methods of treatment
US9452148B2 (en) 2007-01-25 2016-09-27 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment
US10172837B2 (en) 2007-01-25 2019-01-08 NAIA Metabolic, Inc. Insulin sensitisers and methods of treatment
US20150150855A1 (en) * 2012-05-24 2015-06-04 Verva Pharmaceuticals Ltd Method of improving liver function
US20150174108A1 (en) * 2012-05-24 2015-06-25 Vera Pharmaceuticals Ltd Method of weight reduction
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2015012205A1 (en) 2013-07-23 2015-01-29 第一三共株式会社 Medicine for preventing or treating hypertension
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
EP4470609A2 (en) 2019-01-18 2024-12-04 Astrazeneca AB Pcsk9 inhibitors and methods of use thereof

Similar Documents

Publication Publication Date Title
US2783241A (en) S-acylimino-x-substituted-az-i
US2554816A (en) Heterocyclic sulfonamides and methods of preparation thereof
DE69231252T2 (en) Substituted salicylic acid for the treatment of autoimmune diseases
US2595334A (en) Benzothiazolesulfonamides and method of preparing the same
EP0000128A1 (en) Sulfamoylaryl ketones, process for their preparation and their use as medicaments
US2748125A (en) 1-substituted-4-sulfamylpiperazine and method of preparing the same
US4061647A (en) Thiazolidine derivatives
US5449783A (en) Diphenylthiazole derivative
King et al. The reaction of diazoketones with thioamide derivatives
GB1241648A (en) Heterocyclically substituted thiadiazole derivatives, a process for their preparation and their use as herbicides
SU789520A1 (en) Method of preparing n-/4-/-(pyrazole-1-carbonamide)-ethyl/-benzenesulfonyl/ureas
Peak et al. 777. Antituberculous compounds. Part X. Some reactions of quaternary compounds derived from NN-disubstituted thioamides
DE2436263A1 (en) THIAZOLIDE DERIVATIVES AND METHOD FOR THEIR PRODUCTION
US2783240A (en) Heterocyclic sulfonamides
US4376788A (en) Basic ethers of 4-hydroxy-benzophenones acting as beta-blocking agents
US2603649A (en) Heterocyclic sulfonamides and method of preparing the same
NO763502L (en)
US4025508A (en) 6-(Trifluoromethyl)-benzothiadiazines
NO120206B (en)
SU1605924A3 (en) Method of producing benzamide derivatives or their pharmaceutically acceptable salts
US3459742A (en) Sulfanilamide derivatives and processes
US2783242A (en) 5-acylimino-4-substituted-2-benzyl mercapto-belta2-1, 3, 4-thiadiazolines and methods for their preparation
US2577231A (en) Diazine sulfonamides and methods of
US2849479A (en) S-nitrophenyl carboxyalkyl disulfides
US2940980A (en) 5-acylimino-nu-alkyl-4-alkyl-delta2-1, 3, 4-thiadiazoline-2-sulfonamides